Antiangiogenic Treaments
A new type of cancer treatment called antiangiogenic therapy is designed to block blood vessel growth in tumors. In a series of landmark clinical trials, five different antiangiogenic drugs — sunitinib (Sutent®), sorafenib (Nexavar®), bevacizumab (Avastin®), temsirolimus (Torisel®), and everolimus (Afinitor®) — have shown significant benefit in the treatment of advanced kidney cancer. Each of these drugs is now approved by the U.S. Food and Drug Administration (FDA).
Last updated May 29, 2011